Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03677154 · ClinicalTrials.gov registry record · Phase 1
Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma
A Phase 1 study of Diffuse Large B Cell Lymphoma, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 188
- Enrollment target
- 20
- Study locations
NCT03677154: Completed Phase 1 study of Diffuse Large B Cell Lymphoma, sponsored by Hoffmann-La Roche.
NCT03677154 is a Phase 1 study of Diffuse Large B Cell Lymphoma that has completed, run by Hoffmann-La Roche. The registered enrollment target is 188 participants, below the 217-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (13% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03677154, a Phase 1 study of Diffuse Large B Cell Lymphoma, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 188 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab following first-line diffuse large B-cell lymphoma (DLBCL) immunochemotherapy in participants with a best response of stable disease or partial response, or in elderly/unfit participants with previously untreated DLBCL, or subcutaneous mosunetuzumab in combination with polatuzumab vedotin IV in elderly/unfit participants with previously untreated DLBCL.
Conditions Studied
Interventions
- DRUG Polatuzumab Vedotin
- DRUG Tocilizumab
- DRUG Mosunetuzumab Intravenous (IV)
- DRUG Mosunetuzumab Subcutaneous (SC)
Study Locations (20)
Other
- Soroka Medical Center - Beersheba
- Rambam Medical Center - Haifa
- Carmel medical center - Haifa
- Shaare Zedek Medical Center - Jerusalem
- Hadassah Ein-Karem - Jerusalem
- Meir Medical Center - Kfar Saba
- Sheba Medical Center - Ramat Gan
- Uniwersyteckie Centrum Kliniczne - Gdansk
- PRATIA MCM Kraków - Krakow
- Centrum Onkologii Ziemi Lubelskiej im. ?w. Jana z Dukli - Lublin
- Szpital Wojewodzki w Opolu - Opole
- Pusan National University Hospital - Busan
Alabama
- University of Alabama at Birmingham School of Medicine - Birmingham
California
- University of California, Los Angeles (UCLA) - Hematology/Oncology Santa Monica - Santa Monica
Indiana
- Fort Wayne Medical Institute - Fort Wayne
Maryland
- University of Maryland Medical Center - Baltimore
North Carolina
- Duke University - Durham
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Rhode Island
- Rhode Island Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2019-05-23 |
| Est. Completion | 2025-08-07 |
| Phase | Phase 1 |
What the finished NCT03677154 record still lists
NCT03677154 is an interventional study that assigns participants to a tested intervention. The registered 188 participants enrollment target is mid-sized for trials with a published cap, below the 217-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (13% lower).
The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Polatuzumab Vedotin is the first listed.
NCT03677154 names 20 study sites across 9 states, led by Other, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT03677154 about?
NCT03677154 is a clinical study titled "Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma". This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab following first-line diffuse large B-cell lymphoma (DLBCL) immunochemotherapy in participants with a best response of stable disease or partial response, or in elderly/unfit participants with previously ...
What is the current status of trial NCT03677154?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 188 participants. The study started on 2019-05-23. Estimated completion is 2025-08-07.
What conditions does trial NCT03677154 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.
What interventions are being tested in trial NCT03677154?
The interventions under investigation include: Polatuzumab Vedotin (DRUG), Tocilizumab (DRUG), Mosunetuzumab Intravenous (IV) (DRUG), Mosunetuzumab Subcutaneous (SC) (DRUG).
Who is sponsoring clinical trial NCT03677154?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03677154 being conducted?
This trial has 20 study locations across Alabama, California, Indiana, Maryland, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03677154's enrollment target sits among peer trials
188 31st of 114 higher than 84 of 114 other Diffuse Large B Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diffuse Large B Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
RECRUITING · Phase 1
-
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422198 · 188 participants · Phase 3
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
- NCT04469790 · 188 participants · NA
Effects of Multi-day Interruptions in Sitting on Type 2 Diabetes-relevant Outcomes in Children
- NCT04671667 · 188 participants · Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- NCT04853251 · 188 participants · Phase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI